RIGL FY 2023 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$117M-2.8% YoY

Gross Profit

$110M93.9% margin

Operating Income

-$20M-17.5% margin

Net Income

-$25M-21.5% margin

EPS (Diluted)

$-1.44

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$21M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$117M

Total Liabilities

$146M

Stockholders' Equity

-$29M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$120M	-2.8%
Gross Profit	$110M	$118M	-7.4%
Operating Income	-$20M	-$56M	+63.1%
Net Income	-$25M	-$59M	+57.2%